Anifrolumab well-tolerated in patients with systemic lupus erythematosus

Anifrolumab, a new strategy for the treatment of systemic lupus erythematosus, is well-tolerated and has a good safety profile, according to a meta-analysis and systematic review.

After searching Embase, Cochrane, PubMed, and Web of Science databases for randomized controlled trials (RCTs) evaluating the safety of anifrolumab versus placebo in patients with SLE, researchers identified 1160 patients for inclusions.
There were less serious adverse events in the anifrolumab group compared to the placebo group (RR: 0.76, 95% CI: 0.59-0.98, P < 0.03).
The most common adverse events were:
-Upper respiratory tract infection
-Nasopharyngitis
-Bronchitis
-Herpes zoster

Reference
Liu Z, Cheng R, Liu Y. Evaluation of anifrolumab safety in systemic lupus erythematosus: A meta-analysis and systematic review. Front Immunol. 2022;13:996662. doi: 10.3389/fimmu.2022.996662. PMID: 36211347; PMCID: PMC9537685.